IGC Pharma, Inc. (India Globalization Capital, Inc.) — Form 10-Q Summary
Reporting period: Three months ended June 30, 2020, the company’s fiscal first quarter of 2021. Financial amounts below are in U.S. dollars; financial statement figures are in thousands unless stated otherwise. The filing registrant is India Globalization Capital, Inc.
Business context
The company reports Infrastructure and Life Sciences segments. Revenue shifted from Infrastructure, which supplied 94% of revenue in the prior-year quarter, to Life Sciences, which supplied all revenue this quarter. Most current-quarter Life Sciences revenue came from alcohol-based hand sanitizers. COVID-19 restrictions disrupted Infrastructure work and delayed commissioning of hemp-processing equipment.
Financial performance and liquidity
| Metric | Three months ended June 30, 2020 | Prior-year period |
|---|---|---|
| Revenue | $584 | $1,649 |
| Gross profit | $46 | $41 |
| Gross margin | 7.9% | 2.5% |
| Operating loss | $(1,931) | $(1,455) |
| Net loss | $(1,882) | $(1,379) |
| Loss per share, basic and diluted | $(0.05) | $(0.03) |
| Cash used in operating activities | $(3,988) | $(2,872) |
- Revenue fell 65%, as Infrastructure revenue declined from $1.545 million to zero; Life Sciences revenue rose from $104,000 to $584,000. Gross profit increased modestly despite lower sales, reflecting a higher reported gross margin.
- SG&A increased 41% to $1.755 million. Management attributed the increase primarily to a $200,000 derivative-settlement provision, $200,000 payroll accrual, and about $100,000 of additional legal costs. R&D was $222,000, down from $247,000.
- Cash and cash equivalents were $2.703 million at June 30, down $4.555 million from March 31. Separately, marketable securities were $5.098 million; together these balances totaled $7.801 million. Working capital was $13.683 million. The cash decline largely reflected a $2.277 million inventory increase and $944,000 of property and equipment purchases.
- Investing cash outflow was $1.136 million; financing provided $580,000 in loan proceeds. Total liabilities were $3.436 million. The balance sheet reported $630,000 of loans, including $50,000 classified as long-term following reclassification, in addition to lease liabilities.
- Inventory rose to $6.523 million from $4.245 million. Property, plant and equipment, net, rose to $10.603 million from $9.780 million.
Material changes and significant developments
- Business mix changed sharply: Infrastructure revenue was zero in the quarter, while Life Sciences revenue was entirely U.S.-based. The company said hand sanitizer sales accounted for most revenue.
- Shares issued and outstanding increased to 41.196 million from 39.320 million at March 31, including shares issued for an investment. The company reported approximately 3.2 million potentially dilutive securities excluded from diluted EPS as anti-dilutive.
- During the quarter, the company acquired an approximately 19.8% interest in Evolve I for $249,000 recorded as a non-marketable investment. A separate agreement to acquire the remaining interest had not closed by June 30 and remained subject to conditions.
- After quarter-end, on July 30, the FDA permitted a 12-subject Phase 1 trial of IGC-AD1 to proceed. The proposed study is intended to assess safety, tolerability and pharmacokinetics in people with Alzheimer’s-related dementia; it is not evidence of efficacy or eventual approval.
Outlook, risks and contingencies
- Management said existing cash, cash equivalents, marketable securities and other short-term liquidity arrangements should cover working capital and other needs for the next 12 months, while also stating that the company expects to raise money when able. Operating cash burn and declining cash balances remain important considerations.
- Management forecast drastically reduced Infrastructure revenue and unpredictable Life Sciences revenue, with limited visibility into when either segment may stabilize. It expected Infrastructure activity to resume when restrictions permit, including a roughly $1.1 million Kerala road contract expected to take 12–15 months to complete.
- COVID-19 delayed Infrastructure deployment and equipment commissioning; some equipment delivery was described as delayed indefinitely. The filing warned that pandemic precautions could delay clinical trials and increase their cost.
- The company expects R&D expense to increase as IGC-AD1 Phase 1 work begins. Product candidates depend on clinical results, regulatory approvals, intellectual-property protection and adequate funding; the filing cautions that licensed patent applications may not be granted.
- The court approved settlement of the derivative lawsuits on July 6, 2020. The company recorded a $200,000 provision, with the plaintiffs’ payment to be made by the insurer. A separate consolidated shareholder class action remained pending; the motion to dismiss had not been decided.
- Management reported disclosure controls and procedures were effective at quarter-end. It reported no material off-balance-sheet arrangements and no impactful cybersecurity breaches during the quarter.
Important facts for investors to verify
- Whether the $5.098 million in marketable securities is available for near-term operating needs, and how quickly cash burn continues after quarter-end.
- Inventory composition, expected saleability and conversion to cash, particularly the increase in work-in-progress and sanitizer-related stock.
- The actual revenue contribution and sustainability of hand sanitizer sales, and whether Infrastructure operations and the Kerala contract have resumed.
- Funding needs and milestones, including Phase 1 trial costs, trial timing, and the status and conditions of the proposed Evolve acquisition.
- The status and potential exposure of the pending shareholder class action and the insurer-funded derivative settlement.
- Loan terms and classification: the filing describes PPP and EIDL borrowing as well as a $50,000 secured loan; verify outstanding balances, forgiveness status, repayment obligations and any subsequent developments.